Short term relapse risk after switching from fingolimod to ocrelizumab or cladribine - an international cohort study

被引：0
|
作者：
Van Kesteren, Yan [1 ]
Treffts, Johanna [1 ]
Thiel, Sandra [1 ]
Stahmann, Alexander [2 ]
Theis, Lena [1 ]
Magyari, Melinda [3 ]
Celius, Elisabeth [4 ]
Berthele, Achim [5 ]
Giglhuber, Katrin [5 ]
Angstwurm, Klemens [6 ]
Klotz, Luisa [7 ]
Ellwardt, Erik [8 ]
Bittner, Stefan [8 ]
Viehover, Andrea [9 ]
Tackenberg, Bjorn [10 ]
Jurss, Jan [10 ]
Gold, Ralf [1 ]
Ellenberger, David [2 ]
Hellwig, Kerstin [1 ]
机构：
[1] Ruhr Univ Bochum, St Josef Hosp, Dept Neurol, Bochum, Germany
[2] DMSG, Hannover, Germany
[3] Rigshosp, Danish MS Reseach Ctr, Copenhagen, Denmark
[4] Oslo Univ Hosp, Oslo, Norway
[5] Tech Univ Munich, Munich, Germany
[6] Univ Regensburg, Regensburg, Germany
[7] Uniklin Munster, Munster, Germany
[8] Johannes Gutenberg Univ Mainz, Mainz, Germany
[9] Heidelberg Univ, Heidelberg, Germany
[10] Univ Marburg, Marburg, Germany
来源：
NEUROLOGY | 2021年 / 96卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
1822
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Short term relapse risk after switching from natalizumab to ocrelizumab or cladribine - an international cohort study
    Treffts, Johanna
    Van Kesteren, Yan
    Thiel, Sandra
    Stahmann, Alexander
    Magyari, Melinda
    Berthele, Achim
    Giglhuber, Katrin
    Bittner, Stefan
    Ellwardt, Erik
    Angstwurm, Klemens
    Tackenberg, Bjorn
    Jurs, Jan
    Viehover, Andrea
    Klotz, Luisa
    Theis, Lena
    Gold, Ralf
    Ellenberger, David
    Hellwig, Kerstin
    NEUROLOGY, 2021, 96 (15)
  • [2] Fingolimod after natalizumab and the risk of short-term relapse
    Jokubaitis, Vilija G.
    Li, Vivien
    Kalincik, Tomas
    Izquierdo, Guillermo
    Hodgkinson, Suzanne
    Alroughani, Raed
    Lechner-Scott, Jeannette
    Lugaresi, Alessandra
    Duquette, Pierre
    Girard, Marc
    Barnett, Michael
    Grand'Maison, Francois
    Trojano, Maria
    Slee, Mark
    Giuliani, Giorgio
    Shaw, Cameron
    Boz, Cavit
    Spitaleri, Daniele L. A.
    Verheul, Freek
    Haartsen, Jodi
    Liew, Danny
    Butzkueven, Helmut
    NEUROLOGY, 2014, 82 (14) : 1204 - 1211
  • [3] Risk of fingolimod rebound after switching to cladribine or rituximab in multiple sclerosis
    Nygaard, Gro Owren
    Torgauten, Hilde
    Skattebol, Lars
    Hogestol, Einar August
    Sowa, Piotr
    Myhr, Kjell-Morten
    Torkildsen, Oivind
    Celius, Elisabeth Gulowsen
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2022, 62
  • [4] Does switching to fingolimod from natalizumab result in short-term relapse exacerbation?
    Jokubaitis, V. G.
    Li, V.
    Kalincik, T.
    Izquierdo, G.
    Hodgkinson, S.
    Alroughani, R.
    Lechner-Scott, J.
    Lugaresi, A.
    Duquette, P.
    Girard, M.
    Barnett, M.
    Grand'Maison, F.
    Trojano, M.
    Slee, M.
    Giuliani, G.
    Shaw, C.
    Boz, C.
    Haartsen, J.
    Liew, D.
    Butzkueven, H.
    MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 55 - 56
  • [5] Short term disease activity after switching from natalizumab to fingolimod does not predict long term fingolimod efficacy a retrospective study
    Coclitu, C.
    Riggi, F.
    Vaillant, M.
    Casez, O.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 341 - 341
  • [6] Short term efficacy and safety outcomes after switching from Anti-CD20 DMTs to Cladribine in a real-world setting
    O'Neill, Daniel
    Hodgkinson, Suzanne
    NEUROLOGY, 2020, 94 (15)
  • [7] Short-term risk of relapse after a first unprovoked seizure in an adult population
    Alesefir, Walid
    Maillard, Louis
    Klemina, Irina
    Vignal, Jean-Pierre
    Tyvaert, Louise
    NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY, 2020, 50 (02): : 87 - 92
  • [8] Relapse Rates in Patients with Multiple Sclerosis Switching from Interferon to Fingolimod or Glatiramer Acetate: A US Claims Database Study
    Bergvall, Niklas
    Makin, Charles
    Lahoz, Raquel
    Agashivala, Neetu
    Pradhan, Ashish
    Capkun, Gorana
    Petrilla, Allison A.
    Karkare, Swapna U.
    McGuiness, Catherine Balderston
    Korn, Jonathan R.
    PLOS ONE, 2014, 9 (02):
  • [9] Risk of relapse after natalizumab withdrawal Results from the French TYSEDMUS cohort
    Papeix, Caroline
    Vukusic, Sandra
    Casey, Romain
    Debard, Nadine
    Stankoff, Bruno
    Mrejen, Serge
    Uhry, Zoe
    Van Ganse, Eric
    Castot, Anne
    Clanet, Michel
    Lubetzki, Catherine
    Confavreux, Christian
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2016, 3 (06):
  • [10] Short-term safety and efficacy of switching from alemtuzumab to ocrelizumab in MS patients with disease activity after two alemtuzumab courses: an Italian multicentric, real-life study.
    Lapucci, C.
    Frau, J.
    Cocco, E.
    Vercellino, M.
    Cavalla, P.
    Petracca, M.
    Lanzillo, R.
    Grossi, P.
    Ferro, M. T.
    Guaschino, C.
    Zaffaroni, M.
    Tazza, F.
    Novi, G.
    Uccelli, A.
    Inglese, M.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 929 - 929
12345